MedTrace Logo

The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group

NCT00617474 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-03-28

No results posted yet for this study

Summary

The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.

Conditions

  • Transplantation, Kidney

Interventions

DRUG

Erythropoietin

sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    collaborator OTHER

  • Labbafinejhad Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-09-30
Completion
2009-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00617474 on ClinicalTrials.gov